The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research Database.
Details
Serval ID
serval:BIB_C74266759675
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research Database.
Journal
Diagnostics
Working group(s)
Eustar Collaborators
ISSN
2075-4418 (Print)
ISSN-L
2075-4418
Publication state
Published
Issued date
30/01/2024
Peer-reviewed
Oui
Volume
14
Number
3
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
In SSc, ILD is a major cause of morbidity and mortality. We aimed to investigate the performance of DLCO (diffusing capacity of lung carbon monoxide) and FVC (forced vital capacity) delta change (Δ) and baseline values in predicting the development of SSc-ILD.
Longitudinal data of DLCO, FVC, and ILD on the HRCT of SSc patients from the EUSTAR database were evaluated at baseline (t <sub>0</sub> ) and after 12 (±4) (t <sub>1</sub> ) and 24 (±4) (t <sub>2</sub> ) months.
474/17805 patients were eligible for the study (403 females); 46 (9.7%) developed ILD at t <sub>2</sub> . Positivity for anti-topoisomerase antibodies (117 patients) showed an association with ILD development at t <sub>2</sub> (p = 0.0031). Neither the mean t <sub>0</sub> to t <sub>1</sub> change (Δ) of DLCO nor the mean t <sub>0</sub> to t <sub>1</sub> FVCΔ predicted the appearance of ILD at t <sub>2</sub> . Investigating the possible role of baseline DLCO and FVC values in predicting ILD appearance after 24 (±4) months, we observed a moderate predictive capability of t <sub>0</sub> DLCO < 80%, stronger than that of FVC < 80%.
We suggest that an impaired baseline DLCO may be predictive of the appearance of ILD after 2 years of follow-up. This result advances the hypothesis that a reduction in gas exchange may be considered an early sign of lung involvement. However, further rigorous studies are warranted to understand the predictive role of DLCO evaluation in the course of SSc.
Longitudinal data of DLCO, FVC, and ILD on the HRCT of SSc patients from the EUSTAR database were evaluated at baseline (t <sub>0</sub> ) and after 12 (±4) (t <sub>1</sub> ) and 24 (±4) (t <sub>2</sub> ) months.
474/17805 patients were eligible for the study (403 females); 46 (9.7%) developed ILD at t <sub>2</sub> . Positivity for anti-topoisomerase antibodies (117 patients) showed an association with ILD development at t <sub>2</sub> (p = 0.0031). Neither the mean t <sub>0</sub> to t <sub>1</sub> change (Δ) of DLCO nor the mean t <sub>0</sub> to t <sub>1</sub> FVCΔ predicted the appearance of ILD at t <sub>2</sub> . Investigating the possible role of baseline DLCO and FVC values in predicting ILD appearance after 24 (±4) months, we observed a moderate predictive capability of t <sub>0</sub> DLCO < 80%, stronger than that of FVC < 80%.
We suggest that an impaired baseline DLCO may be predictive of the appearance of ILD after 2 years of follow-up. This result advances the hypothesis that a reduction in gas exchange may be considered an early sign of lung involvement. However, further rigorous studies are warranted to understand the predictive role of DLCO evaluation in the course of SSc.
Keywords
computed tomography (CT), interstitial lung disease, pulmonary function test, scleroderma
Pubmed
Web of science
Open Access
Yes
Create date
15/02/2024 17:52
Last modification date
02/03/2024 8:10
Usage data
